Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HiCM-188 in Ischemic Heart Failure
NCT05566600Phase 1Recruiting
- Sponsor
- Help Therapeutics
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HiCM-188 in Ischemic Heart Failure (IHF) (4 arms), sponsored by Help Therapeutics. Primary endpoint: Incidence and severity of adverse events at 1 month. Started Oct 2022; status: recruiting.
02
Drugs
HiCM-188
03
Conditions
Ischemic Heart Failure (IHF)
Beyond the preview
Go deeper on NCT05566600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566600.